
Insilico Medicine, a biotechnology company based in Hong Kong, announced that human patients have begun receiving the drug INS018_055, an anti-fibrotic small molecule inhibitor…
Read More
Your trusted source of news.
Insilico Medicine, a biotechnology company based in Hong Kong, announced that human patients have begun receiving the drug INS018_055, an anti-fibrotic small molecule inhibitor…
Read More